Floatz logo

Alisertib

Primary Myelofibrosis

Northwestern UniversitySmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Primary Myelofibrosis cohort.

Asset / SponsorPhaseRating
Ruxolitinib
OHSU Knight Cancer Institute
Phase 4BBB
Fludarabine
University of Utah
Phase 2BB
TACROLIMUS
City of Hope Medical Center
Phase 2BB
Panobinostat
OHSU Knight Cancer Institute
Phase 4BB
Cyclophosphamide
City of Hope Medical Center
Phase 2B

View all 50 →

Same molecule, other indications

Alisertib is also rated in:

Burkitt lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
mantle cell lymphomaDormant
BB
Indicative ·
69 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →